๐๏ธ Verified NIH Record โข Updated 2026-03-30
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia (NCT03431090)
HAPLEUK17, Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
๐ต Active, Not Recruiting Phase1 / Phase2 โ๏ธ Medical Device Protocol Sponsor: Nationwide Children's Hospital
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an ฮฑฮฒTCR/CD19+ cell depleted graft.
Who can join: Review the eligibility criteria below.
Location: Nationwide Children's Hospital โ Columbus, Ohio
Age range: Not specified to 30 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Nationwide Children's Hospital โ Columbus, Ohio
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Myelodysplasia clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.